[重度哮喘治疗的创新]
[Innovations in the treatment of severe asthma].
作者信息
Buss Guillaume, Spertini François
机构信息
Service d'immunologie et allergie, Département de médecine et des laboratoires, CHUV, 1011 Lausanne.
出版信息
Rev Med Suisse. 2017 Jan 11;13(544-545):18-19.
PMID:28703528
Abstract
In severe asthma, there is a real need for new effective therapies offering a good safety and tolerance profile. Mepolizumab is a humanized anti-interleukin-5 monoclonal antibody, available in Switzerland since 2016 for treatment of severe adult eosinophilic asthma. Other monoclonal antibodies, such as dupilumab, are being developed in the field of asthma.
摘要
在重度哮喘中，确实需要有新的有效疗法，且这些疗法要有良好的安全性和耐受性。美泊利单抗是一种人源化抗白细胞介素-5单克隆抗体，自2016年起在瑞士可用于治疗重度成人嗜酸性粒细胞性哮喘。其他单克隆抗体，如度普利尤单抗，也正在哮喘领域进行研发。
Zotero 插件